PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31688897-12	2020	Moreover, we found significant associations between CDAD group and metabolic syndrome, prior use of antibiotic in the last 3 months, NAFLD and high serum levels of C-reactive protein.	cdad	52-56	C-reactive protein	Homo sapiens	164-182
15871884-11	2005	Albumin level was another major risk factor for CDAD, with an overwhelming 68% of CDAD patients having albumin levels below 3 g/dL (mean 2.68 g/dL) compared with a mean of 3.22 g/dL in the control group (t = 4.210; df = 51; P < .001).	cdad	48-52	albumin	Homo sapiens	0-7
15871884-11	2005	Albumin level was another major risk factor for CDAD, with an overwhelming 68% of CDAD patients having albumin levels below 3 g/dL (mean 2.68 g/dL) compared with a mean of 3.22 g/dL in the control group (t = 4.210; df = 51; P < .001).	cdad	48-52	albumin	Homo sapiens	103-110
15871884-11	2005	Albumin level was another major risk factor for CDAD, with an overwhelming 68% of CDAD patients having albumin levels below 3 g/dL (mean 2.68 g/dL) compared with a mean of 3.22 g/dL in the control group (t = 4.210; df = 51; P < .001).	cdad	82-86	albumin	Homo sapiens	0-7
15871884-11	2005	Albumin level was another major risk factor for CDAD, with an overwhelming 68% of CDAD patients having albumin levels below 3 g/dL (mean 2.68 g/dL) compared with a mean of 3.22 g/dL in the control group (t = 4.210; df = 51; P < .001).	cdad	82-86	albumin	Homo sapiens	103-110
34452896-3	2021	OBJECTIVE: To determine the role of the serum albumin to creatinine ratio (sACR) in predicting the 30-day all-cause mortality of patients with CDAD in comparison with other known severity scores of CDAD.	cdad	143-147	albumin	Homo sapiens	40-53
27091869-7	2016	The incidence of CDAD was 3%, 1.3%, and 1.2% in patients who received a PPI, H2RA, and no AST, respectively (4/142 vs 1/70 vs 1/80; OR for PPI vs H2RA = 1.92; 95% CI = 0.21-17.47).	cdad	17-21	solute carrier family 17 member 5	Homo sapiens	90-93
28764868-6	2017	As a use case, we compare the efficacy of lanthionine synthetase C-like 2 (LANCL2), a novel immunoregulatory target with promising efficacy in inflammatory bowel disease (IBD), activation with antibiotics, fecal microbiome transplantation and anti-toxin antibodies in the treatment of CDAD.	cdad	285-289	LanC (bacterial lantibiotic synthetase component C)-like 2	Mus musculus	75-81
20398664-4	2010	In the present study, we hypothesize that TcdA and TcdB trigger inflammasome-dependent interleukin (IL)-1beta production, which contributes to the pathogenesis of CDAD.	cdad	163-167	interleukin 1 beta	Mus musculus	87-109
22944235-12	2012	According to multivariate analyses, the predictors of CDAD included prior hospitalization (P < 0.01, OR = 0.002), CRP(P = 0.008, OR = 3.465), NSAID (P = 0.015, OR = 13.950) and WBC (P = 0.003, OR = 8.063).	cdad	54-58	C-reactive protein	Homo sapiens	117-120
22944235-13	2012	CONCLUSION: The administration of NSAID, elevated CRP and abnormal WBC are significantly associated with CDAD.	cdad	105-109	C-reactive protein	Homo sapiens	50-53
21449161-5	2011	It seems to be the first report of the association of MTX treatment with CDAD.	cdad	73-77	metaxin 1	Homo sapiens	54-57
18067688-9	2008	RESULTS: The evidence for an association between fluoroquinolone use and CDAD, especially CDAD due to the hypervirulent NAP1 strain or the polymerase chain reaction ribotype 027, is becoming stronger.	cdad	73-77	nucleosome assembly protein 1 like 1	Homo sapiens	120-124
20435915-3	2010	Thuricin CD is produced by Bacillus thuringiensis DPC 6431, a bacterial strain isolated from a human fecal sample, and it consists of two distinct peptides, Trn-alpha and Trn-beta, that act synergistically to kill a wide range of clinical C. difficile isolates, including ribotypes commonly associated with CDAD (e.g., ribotype 027).	cdad	307-311	mitochondrially encoded tRNA glycine	Homo sapiens	157-166
18067688-9	2008	RESULTS: The evidence for an association between fluoroquinolone use and CDAD, especially CDAD due to the hypervirulent NAP1 strain or the polymerase chain reaction ribotype 027, is becoming stronger.	cdad	90-94	nucleosome assembly protein 1 like 1	Homo sapiens	120-124
17072575-5	2006	Administration of interleukin-2 either during hospitalization or in the 30 days preceding admission was seven times more likely to have occurred in CDAD cases (p = 0.04), raising the question of whether or not this agent increases risk.	cdad	148-152	interleukin 2	Homo sapiens	18-31